Veterinary Medicines

MGVAX, emulsione oleosa iniettabile per polli

Authorised
  • Mycoplasma gallisepticum, strain S6, Inactivated
Download as PDF

Product identification

Medicine name:
MGVAX, emulsione oleosa iniettabile per polli
Active substance:
  • Mycoplasma gallisepticum, strain S6, Inactivated
Target species:
  • Chicken
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Mycoplasma gallisepticum, strain S6, Inactivated
    5.00
    log2 haemagglutination inhibiting unit(s)
    /
    0.50
    millilitre(s)
Pharmaceutical form:
  • Emulsion for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Chicken
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI01AB03
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Italy
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Boehringer Ingelheim Animal Health Italia S.p.A. In Breve Boehringer Ingelheim Ah It S.p.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Boehringer Ingelheim Animal Health Italia S.p.A. In Breve Boehringer Ingelheim Ah It S.p.A.
Responsible authority:
  • Ministry Of Health
Authorisation number:
This information is not available for this product.
Date of authorisation status change:

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Italian (PDF)
Published on: 11/04/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."